We showed that tumor-derived MVs carrying the MUC1 tumor glycoantigen employed as immunogen, restored phagosomal pH close to neutrality, allowing cross-presentation of the tumor associated MUC1 glycoantigen and the activation of MUC1 specific CD8+ T cell response. This evidence concerns the gene CD8A and neoplasm.